Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain scans reveal how new combo drug curbs appetite

NCT ID NCT06267092

Symptom relief Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study tested how CagriSema (a combination of cagrilintide and semaglutide) affects appetite and brain activity in 164 adults with overweight or obesity. Participants received either the drug, a placebo, or no medicine, and researchers measured appetite scores and brain responses using scans. The goal was to understand the mechanisms behind appetite control, not to achieve weight loss directly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CagriSema (cagrilintide and semaglutide combination)
What this could lead to
If it works, this could help explain how this combination medicine reduces appetite and changes brain activity, potentially leading to better weight-loss treatments.
What could go wrong
This is an early Phase 1 study focused on measuring appetite and brain signals, not weight loss itself. Results may not translate to long-term benefits or apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

164 people

The number who actually took part.

Started

Feb 2024

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female * Aged 18-65 years (both inclusive) at the time of signing informed consent * Right-handed as evaluated by the Edinburgh Handedness Inventory * Body weight less than or equal to 180 kilogram at screening For Part A: * A score of 7 or less on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire * Body mass index between 18.5 and 24.9 kilogram per meter square (both inclusive) at screening For Part B: * A score of 8 or more on the 16-item Disinhibition subscale of the Three Factor Eating Questionnaire * Body mass index equal to or above 27.0 kilogram per meter square. Overweight should be due to excess adipose tissue, as judged by the investigator Exclusion Criteria: * Contraindication for magnetic resonance scanning For Part B: * Glycated haemoglobin greater than or equal to 6.5 % (48 millimoles per mole) at screening * History of type 1 or type 2 diabetes mellitus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight

Contacts and locations

Locations

  • Charité - Campus Charité Mitte - Charité Research Organisation GmbH

    Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.